NEW ENZYME – NEW THERAPY
Pharmact Holding AG is an innovative company in human medical research and drug development. Our subsidiaries and strategic partners work together to set new standards in pharmaceutical development and the application of the therapies we have created.
Our aim is to sustainably improve healthcare through scientific excellence and innovative solutions.
.
BUILDING HEALTH TOGETHER
Our globally pioneering therapy is based on our designed drug, a genetically optimized enzyme with exceptionally high efficacy.
In this way, we enable groundbreaking progress in medicine – for a better, healthier future.
By continuously expanding our network, we create valuable synergies between science and industry.
OUR MISSION
We have developed therapeutic solutions to alleviate or cure familial hypercholesterolemia. An opportunity to offer patients an efficient and reproducible treatment for this condition.
Our research and development, in collaboration with universities, experienced medical professionals, and medical institutes, form the foundation for new approaches to healing.
NEWS PRODUCTS
Screening for metabolic diseases on early stages
The effective therapy of diabetes mellitus and arteriosclerosis as well as their sequelae is one of the greatest medical challenges of our time. More…
NEW PROJECTS
New substance in registration process
Arteriosclerosis is a silent disease that partially leads to calcifying hardening of the arterial system. Pharmact has developed a specific drug that is available from the beginning of Q2. 2020. The substance has now been entered the drug approval process.
EUROPE
Pharmact GmbH
Int´l Distribution
Headquarters
Phone: +49 621-1806178-0
E-Mail: sales@pharmact.de
USA
Pharmact Healthcare Inc.
Distribution
USA / CAN
Phone: +1 813 200 5884
E-Mail:
sales@pharmact-us.com